Canagliflozin/teneligliptin - Mitsubishi Tanabe Pharma Corporation
Alternative Names: CANALIA; MT-2412; TA-7284/MP-513Latest Information Update: 28 Aug 2025
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Antihyperglycaemics; Glucosides; Ketones; Piperazines; Pyrazoles; Small molecules; Thiazolidines; Thiophenes
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2025 Preregistration for Type 2 diabetes mellitus in Asia (PO) before August 2025 (Mitsubishi Tanabe Pharma Corporation pipeline, August 2025)
- 17 Feb 2025 Registered for Type 2 diabetes mellitus in Japan (PO, Fast dissolve)
- 05 Feb 2019 Chemical structure information added